Ribosomal protein L21 pseudogene 90 (RPL21P90)

RPL21P90 is a processed pseudogene, meaning it is a non-functional genomic sequence derived from the reverse transcription and integration of the mRNA of a functional gene—in this case, RPL21, which encodes a component of the 60S large ribosomal subunit[1][2][5]. RPL21P90 is one of many processed pseudogenes for ribosomal proteins scattered throughout the human genome and lacks protein-coding capability[5][8]. As a pseudogene, it is not involved in cellular function, pathogenesis, or therapeutic targeting[1][2][5][8]. Pseudogenes like RPL21P90 arise from genomic integration events, typically through retrotransposition, resulting in sequences highly homologous to their parent genes but generally silenced or non-functional due to mutations or lack of regulatory elements[5]. The functional RPL21 gene encodes a structural component of the cytoplasmic 60S ribosomal subunit, but RPL21P90 itself lacks coding potential and thus does not contribute to ribosome structure or function[1][2][5]. There are no documented biological functions, associated diseases, known drug interactions, or mechanisms of action related to RPL21P90[1][2][5][8]. Pseudogenes are not classified as canonical therapeutic targets, and there is no evidence that RPL21P90 acts as a biomarker or presents safety concerns relevant to drug development[1][2][5][8].

Other names

RPL21_37_1084RPL21P90